Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/20889
Title: | Routine HbA1c among hematology and oncology inpatients: Diabetes-status and hospital-outcomes. | Austin Authors: | Chiu, Wei-Ling;Churilov, Leonid ;Lim, Chee-Hau;Tan, Alanna ;Nedumannil, Rithin;Lau, Lik-Hui;Lew, Jeremy;Hachem, Mariam;Kong, Alvin;Robbins, Raymond J ;Sutcliffe, Harvey;Lam, Que T ;Lee, Andrew;Djukiadmodjo, Frida;Nanayakkara, Natalie;Zajac, Jeffrey D ;Ekinci, Elif I | Affiliation: | Medicine (University of Melbourne) University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia Clinical Informatics Unit, Austin Health, Heidelberg, Victoria, Australia Pathology Department of Strategy, Quality & Service Redesign, Austin Health, Heidelberg, Victoria, Australia Endocrinology The Florey Institute of Neuroscience and Mental Health |
Issue Date: | 10-May-2019 | Date: | 2019-05-10 | Publication information: | Diabetes Research and Clinical Practice 2019; 152: 71-78 | Abstract: | Using routine HbA1c measurement to determine the prevalence of diabetes mellitus (known and previously unrecognized) and their hospital outcomes among hematology and oncology inpatients. This was a prospective, observational study. Routine automated HbA1c testing was performed in all hematology and oncology inpatients aged ≥54 years at a tertiary hospital, July 2013-January 2015. The outcome measures were: (i) prevalence of known and previously unrecognized diabetes, and (ii) hospital outcomes: length-of-stay (LOS), intensive-care-unit (ICU) admission, 30-day/18-month readmission, and 18-month mortality. Over the 18-month study period, 1076 inpatients aged ≥54 years were admitted to hematology (n = 298) and oncology (n = 778) units: 21% had known diabetes and 7% had previously unrecognized diabetes. Patients with known diabetes had a longer LOS (IRR: 1.18, 95%CI: 1.02-1.37, p = 0.03), compared to those without diabetes, adjusting for age, hemoglobin level, estimated-glomerular-filtration-rate, admission specialty unit, Charlson's comorbidity index score, and glucocorticoid exposure. No significant differences were observed in ICU admission, 30-day/18-month readmission, and 18-month mortality among patients with known, previously unrecognized and no diabetes (p ≥ 0.05). Approximately one in five hematology or oncology inpatients aged ≥54 years had known diabetes, and one in fourteen had previously unrecognized diabetes. Those with known diabetes had a longer hospital stay. Routine HbA1c measurement is can be useful for identifying previously unrecognized diabetes, particularly among patients with high glucocorticoid exposure. Further study is required to determine cost-effectiveness in screening for unrecognized diabetes and optimal management of these patients. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/20889 | DOI: | 10.1016/j.diabres.2019.05.002 | ORCID: | 0000-0003-2372-395X |
Journal: | Diabetes Research and Clinical Practice | PubMed URL: | 31082446 | Type: | Journal Article | Subjects: | Hematology inpatients Hospital outcomes Known diabetes Oncology inpatients Routine HbA1c Unrecognized diabetes |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.